166 related articles for article (PubMed ID: 34628929)
1. ALK-positive histiocytosis with disseminated disease responded to alectinib: a case report.
Tian Y; Li J; Liu B; Xie H; Zheng M; Yao W
Ann Palliat Med; 2021 Sep; 10(9):10095-10101. PubMed ID: 34628929
[TBL] [Abstract][Full Text] [Related]
2. ALK-rearranged histiocytosis: Report of two cases with involvement of the central nervous system.
Rossi S; Gessi M; Barresi S; Tamburrini G; Giovannoni I; Ruggiero A; Colafati GS; Frassanito P; Carboni A; Alexandre A; Cacchione A; Trombatore P; Diomedi-Camassei F; Gaspari S; Gianno F; Marras CE; Cecinati V; Carai A; Mastronuzzi A; Alaggio R
Neuropathol Appl Neurobiol; 2021 Oct; 47(6):878-881. PubMed ID: 34048085
[TBL] [Abstract][Full Text] [Related]
3. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion.
Chang KTE; Tay AZE; Kuick CH; Chen H; Algar E; Taubenheim N; Campbell J; Mechinaud F; Campbell M; Super L; Chantranuwat C; Yuen ST; Chan JKC; Chow CW
Mod Pathol; 2019 May; 32(5):598-608. PubMed ID: 30573850
[TBL] [Abstract][Full Text] [Related]
4. ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology.
Kashima J; Yoshida M; Jimbo K; Izutsu K; Ushiku T; Yonemori K; Yoshida A
Am J Surg Pathol; 2021 Mar; 45(3):347-355. PubMed ID: 32826530
[TBL] [Abstract][Full Text] [Related]
5. Multisystem ALK-positive histiocytosis: a multi-case study and literature review.
Liu W; Liu HJ; Wang WY; Tang Y; Zhao S; Zhang WY; Yan JQ; Liu WP
Orphanet J Rare Dis; 2023 Mar; 18(1):53. PubMed ID: 36915094
[TBL] [Abstract][Full Text] [Related]
6. Distinct Clinicopathologic Features and Possible Pathogenesis of Localized ALK-positive Histiocytosis of the Breast.
Osako T; Kurisaki-Arakawa A; Dobashi A; Togashi Y; Baba S; Shiozawa S; Ishigame H; Ishige H; Ohno S; Ishikawa Y; Takeuchi K
Am J Surg Pathol; 2022 Mar; 46(3):344-352. PubMed ID: 34482333
[TBL] [Abstract][Full Text] [Related]
7. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
8. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
9. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
10. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
11. Case report: Systemic presentation of ALK-positive Histiocytosis.
Wei Y; Zhang R; Lin D; Chen X; Li L; Huang H
Front Oncol; 2024; 14():1366766. PubMed ID: 38706599
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Rare Systemic and Aggressive ALK-Positive Histiocytosis With Recurrent Pancreatitis Treating by
Li Y; Shi C; Wu Y; He M; Xia X; Liu J; Jiang Y
Front Med (Lausanne); 2022; 9():840407. PubMed ID: 35665359
[TBL] [Abstract][Full Text] [Related]
13. A Rare Case of Tracheal Crystal-Storing Histiocytosis Associated with Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue.
Kimura S; Oyama Y; Ziyao W; Waseda R; Nishino N; Sakata T; Takeshita M
Int J Surg Pathol; 2022 Aug; 30(5):543-550. PubMed ID: 35075931
[TBL] [Abstract][Full Text] [Related]
14. Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib.
Zhou Y; Hurtado-Castillo M; Pandey O
Front Med (Lausanne); 2023; 10():1288849. PubMed ID: 38093982
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of intracranial Langerhans cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a case report.
Kim S; Lee M; Shin HJ; Lee J; Suh YL
Childs Nerv Syst; 2016 May; 32(5):893-6. PubMed ID: 26466952
[TBL] [Abstract][Full Text] [Related]
16. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.
Kemps PG; Picarsic J; Durham BH; Hélias-Rodzewicz Z; Hiemcke-Jiwa L; van den Bos C; van de Wetering MD; van Noesel CJM; van Laar JAM; Verdijk RM; Flucke UE; Hogendoorn PCW; Woei-A-Jin FJSH; Sciot R; Beilken A; Feuerhake F; Ebinger M; Möhle R; Fend F; Bornemann A; Wiegering V; Ernestus K; Méry T; Gryniewicz-Kwiatkowska O; Dembowska-Baginska B; Evseev DA; Potapenko V; Baykov VV; Gaspari S; Rossi S; Gessi M; Tamburrini G; Héritier S; Donadieu J; Bonneau-Lagacherie J; Lamaison C; Farnault L; Fraitag S; Jullié ML; Haroche J; Collin M; Allotey J; Madni M; Turner K; Picton S; Barbaro PM; Poulin A; Tam IS; El Demellawy D; Empringham B; Whitlock JA; Raghunathan A; Swanson AA; Suchi M; Brandt JM; Yaseen NR; Weinstein JL; Eldem I; Sisk BA; Sridhar V; Atkinson M; Massoth LR; Hornick JL; Alexandrescu S; Yeo KK; Petrova-Drus K; Peeke SZ; Muñoz-Arcos LS; Leino DG; Grier DD; Lorsbach R; Roy S; Kumar AR; Garg S; Tiwari N; Schafernak KT; Henry MM; van Halteren AGS; Abla O; Diamond EL; Emile JF
Blood; 2022 Jan; 139(2):256-280. PubMed ID: 34727172
[TBL] [Abstract][Full Text] [Related]
17. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
Yoshida T; Hida T; Yatabe Y
Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
[TBL] [Abstract][Full Text] [Related]
18. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study).
Takeuchi K; Togashi Y; Kamihara Y; Fukuyama T; Yoshioka H; Inoue A; Katsuki H; Kiura K; Nakagawa K; Seto T; Maemondo M; Hida T; Harada M; Ohe Y; Nogami N; Yamamoto N; Nishio M; Tamura T
Ann Oncol; 2016 Jan; 27(1):185-92. PubMed ID: 26487585
[TBL] [Abstract][Full Text] [Related]
19. Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.
Metro G; Lunardi G; Bennati C; Chiarini P; Sperduti I; Ricciuti B; Marcomigni L; Costa C; Crinò L; Floridi P; Gori S; Chiari R
J Neurooncol; 2016 Sep; 129(2):355-61. PubMed ID: 27324494
[TBL] [Abstract][Full Text] [Related]
20. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
Ou SH; Milliken JC; Azada MC; Miller VA; Ali SM; Klempner SJ
Lung Cancer; 2016 Jan; 91():70-2. PubMed ID: 26464158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
